Jacobs Levy Equity Management’s Altimmune ALT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-124,821	Closed	-$451K	–	955
2025 Q4	$451K	Buy	+124,821	New	+$544K	﹤0.01%	815
2024 Q3	–	Sell	-86,949	Closed	-$578K	–	947
2024 Q2	$578K	Sell	86,949 -345,717	-80%	-$2.55M	﹤0.01%	819
2024 Q1	$4.4M	Buy	432,666 +325	+0.1%	+$3.31K	0.02%	451
2023 Q4	$4.86M	Buy	+432,341	New	+$1.81M	0.02%	431
2017 Q2	–	Sell	-33	Closed	-$8K	–	921
2017 Q1	$8K	Buy	+33	New	+$17.7K	﹤0.01%	909
2016 Q1	–	Sell	-172	Closed	-$98K	–	1099
2015 Q4	$98K	Buy	+172	New	+$85.7K	﹤0.01%	740
2014 Q4	–	Sell	-384	Closed	-$205K	–	811
2014 Q3	$205K	Buy	384 +4	+1%	+$2.09K	﹤0.01%	741
2014 Q2	$161K	Sell	380 -71	-16%	-$32.1K	﹤0.01%	771
2014 Q1	$248K	Buy	451 +342	+314%	+$200K	﹤0.01%	783
2013 Q4	$61K	Sell	109 -31	-22%	-$18.5K	﹤0.01%	921
2013 Q3	$88K	Sell	140 -629	-82%	-$360K	﹤0.01%	893
2013 Q2	$367K	Buy	+769	New	+$381K	0.01%	786

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jacobs Levy Equity Management's ALT Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Altimmune (ALT) in Q1 2026, closing a stake of 124,821 shares — an estimated $451K sold.

Jacobs Levy Equity Management first reported a position in ALT in Q2 2013 and held it in 12 quarters. The position peaked at $4.86M in Q4 2023. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Jacobs Levy Equity Management reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
Jacobs Levy Equity Management sold 124,821 Altimmune shares in Q1 2026, an estimated $451K.
Jacobs Levy Equity Management first reported a position in Altimmune in Q2 2013 and held it in 12 quarters.
Jacobs Levy Equity Management's Altimmune position peaked at $4.86M in Q4 2023.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.